Damora Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.12%
- Market cap
- $1.36B
- 61.9M shares
- Filings
- 353
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2022derivedN/M FY22 yoy
Q3 2026N/M FY25 yoy
Q3 2026+1,717.5% FY25 yoy
- $1.36B
- —
- —
- 2.8×
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Net Interest Income
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,167,000 | reported | |
| FY 2024 | 2024-12-31 | $844,000 | reported | |
| FY 2023 | 2023-12-31 | $1,689,000 | reported | |
| FY 2022 | 2022-12-31 | $722,000 | reported | |
| FY 2021 | 2021-12-31 | $156,000 | reported |
Pharmaceutical preparations
Damora Therapeutics, Inc. is the 126th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ANABAnaptysbio, Inc$234.6M157.0%5.6%$1.4BOCULOcular Therapeutix, Inc$52.0M18.5%511.9%$1.4BAAPGAscentage Pharma Group InternationalFiscal 2024 figures———$1.4BMLYSMineralys Therapeutics, Inc.———$1.4B
DMRADamora Therapeutics, Inc. (this company)———$1.4B
AVLNAvalyn Pharma Inc.———$1.4BINVAInnoviva, Inc.$411.3M14.7%65.9%$1.3BMNKDMannkind Corp$349.0M22.2%1.7%$1.3BKARDKardigan, Inc.———$1.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Damora Therapeutics, Inc. · CIK 1800315 · Engraved from SEC EDGAR